Treating patients with castration-resistant prostate cancer with a poxvirus-based PSA vaccine followed by hormone therapy with nilutamide improved overall survival, according to recent data.
Fertility-preserving hormonal therapy use for early-stage endometrial cancer increased from 5.2% in 2004 to 13.8% in 2020. Survival with that treatment was comparable to that with hysterectomy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results